Amicus Therapeutics Net Income 2007-2021 | FOLD
For a detailed definition, formula and example for Net Income, check out our new background page here.
Amicus Therapeutics net income from 2007 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Amicus Therapeutics Annual Net Income
(Millions of US $) |
| 2020 |
$-277 |
| 2019 |
$-356 |
| 2018 |
$-349 |
| 2017 |
$-284 |
| 2016 |
$-200 |
| 2015 |
$-132 |
| 2014 |
$-69 |
| 2013 |
$-60 |
| 2012 |
$-49 |
| 2011 |
$-44 |
| 2010 |
$-55 |
| 2009 |
$-7 |
| 2008 |
$-39 |
| 2007 |
$-42 |
| 2006 |
$-42 |
| 2005 |
$-20 |
Amicus Therapeutics Quarterly Net Income
(Millions of US $) |
| 2021-06-30 |
$-51 |
| 2021-03-31 |
$-66 |
| 2020-12-31 |
$-71 |
| 2020-09-30 |
$-64 |
| 2020-06-30 |
$-52 |
| 2020-03-31 |
$-89 |
| 2019-12-31 |
$-90 |
| 2019-09-30 |
$-62 |
| 2019-06-30 |
$-85 |
| 2019-03-31 |
$-120 |
| 2018-12-31 |
$-78 |
| 2018-09-30 |
$-159 |
| 2018-06-30 |
$-62 |
| 2018-03-31 |
$-50 |
| 2017-12-31 |
$-69 |
| 2017-09-30 |
$-112 |
| 2017-06-30 |
$-48 |
| 2017-03-31 |
$-55 |
| 2016-12-31 |
$-59 |
| 2016-09-30 |
$-47 |
| 2016-06-30 |
$-51 |
| 2016-03-31 |
$-44 |
| 2015-12-31 |
$-43 |
| 2015-09-30 |
$-38 |
| 2015-06-30 |
$-27 |
| 2015-03-31 |
$-24 |
| 2014-12-31 |
$-21 |
| 2014-09-30 |
$-17 |
| 2014-06-30 |
$-15 |
| 2014-03-31 |
$-16 |
| 2013-12-31 |
$-12 |
| 2013-09-30 |
$-15 |
| 2013-06-30 |
$-15 |
| 2013-03-31 |
$-17 |
| 2012-12-31 |
$-10 |
| 2012-09-30 |
$-16 |
| 2012-06-30 |
$-9 |
| 2012-03-31 |
$-13 |
| 2011-12-31 |
$-9 |
| 2011-09-30 |
$-10 |
| 2011-06-30 |
$-13 |
| 2011-03-31 |
$-13 |
| 2010-12-31 |
$-15 |
| 2010-09-30 |
$-15 |
| 2010-06-30 |
$-11 |
| 2010-03-31 |
$-13 |
| 2009-12-31 |
$33 |
| 2009-09-30 |
$-13 |
| 2009-06-30 |
$-14 |
| 2009-03-31 |
$-12 |
| 2008-12-31 |
$-14 |
| 2008-09-30 |
$-8 |
| 2008-06-30 |
$-9 |
| 2008-03-31 |
$-8 |
| 2007-12-31 |
$-12 |
| 2007-09-30 |
$-10 |
| 2007-06-30 |
$-10 |
| 2007-03-31 |
$-10 |
| 2006-09-30 |
$-12 |
| 2006-06-30 |
$-28 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$2.852B |
$0.261B |
|
AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilizeproteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease.
|
